Abstract: Movement DisordersVolume 13, Issue 1 p. 2-4 Editorial The role of spectroscopy in parkinsonism Dr. Charles Davie MRCP, MD, Corresponding Author Dr. Charles Davie MRCP, MD Institute of Neurology, London, U.K.Institute of Neurology, Queen Square, London, WC1N 3BGSearch for more papers by this author Dr. Charles Davie MRCP, MD, Corresponding Author Dr. Charles Davie MRCP, MD Institute of Neurology, London, U.K.Institute of Neurology, Queen Square, London, WC1N 3BGSearch for more papers by this author First published: 04 November 2004 https://doi.org/10.1002/mds.870130104Citations: 67AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–184. 10.1136/jnnp.55.3.181 CASPubMedWeb of Science®Google Scholar 2 Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 1991; 18: 275–278. 10.1017/S0317167100031814 CASPubMedWeb of Science®Google Scholar 3 Litvan I, Mangone CA, McKee A, et al. J Neurol Neurosurg Psychiatry 1996; 60: 615–620. 10.1136/jnnp.60.6.615 PubMedWeb of Science®Google Scholar 4 Ansorge O, Lees AJ, Brooks DJ, Daniel SE Multiple system atrophy presenting as progressive supranuclear palsy and vice versa: two unusual cases [Abstract]. Mov Disord 1997; 12(suppl): 358. Google Scholar 5 Frahm J, Michaelis T, Merboldt KD, Bruhn H, Gyngell ML, Hänicke W. Improvements in localised proton NMR spectroscopy of human brain, water suppression, short echo times and 1 mL resolution. J Magn Reson 1990; 90: 464–473. 10.1016/0022-2364(90)90051-A CASWeb of Science®Google Scholar 6 Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterisation of plaques in multiple sclerosis. Neurology 1991; 41: 1251–1256. 10.1212/WNL.41.8.1251 PubMedWeb of Science®Google Scholar 7 Chong WK, Sweeney B, Wilkinson ID, et al. Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic and MR imaging findings. Radiology 1993; 188: 119–124. 10.1148/radiology.188.1.8099750 CASPubMedWeb of Science®Google Scholar 8 Gideon P, Henriksen O, Sperling B, et al. Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. Stroke 1992; 23: 1566–1572. 10.1161/01.STR.23.11.1566 CASPubMedWeb of Science®Google Scholar 9 Demaerel P, Johannik K, Van Hecke PV, et al. LocalisedH1 NMR spectroscopy in 50 cases of newly diagnosed intracranial tumours. J Comput Assist Tomogr 1991b; 15: 67–76. 10.1097/00004728-199101000-00009 PubMedWeb of Science®Google Scholar 10 Shino A, Matsuda M, Morikawa S, Inubushi T, Akiguchi I, Handa J. Proton magnetic resonance spectroscopy with dementia. Surg Neurol 1993; 39: 143–147. 10.1016/0090-3019(93)90093-G PubMedWeb of Science®Google Scholar 11 Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW. What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectoscopy? J Neurol 1994; 41: 354–371. 10.1007/BF02033352 Web of Science®Google Scholar 12 Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hänicke W, Sauter R. Localised proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989b; 11: 47–63. 10.1002/mrm.1910110105 CASPubMedWeb of Science®Google Scholar 13 Birken DL, Oldendorf WH., N-acetyl-aspartic acid: a literature review of a compound prominent in 1H NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989; 13: 23–31. 10.1016/S0149-7634(89)80048-X CASPubMedWeb of Science®Google Scholar 14 Unrejak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13: 981–989. PubMedWeb of Science®Google Scholar 15 Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118: 1583–1592. 10.1093/brain/118.6.1583 PubMedWeb of Science®Google Scholar 16 Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HBW. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magn Reson Imaging 1993; 11: 107–118. 10.1016/0730-725X(93)90418-D CASPubMedWeb of Science®Google Scholar 17 Holshouser BA, Komu M, Moller HE, et al. Localised proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. Magn Reson Med 1995; 33: 589–594. 10.1002/mrm.1910330502 CASPubMedWeb of Science®Google Scholar 18 Clarke CE, Lowry M, Horsman A. Unchanged N-acetyl aspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov Disord (in press). Google Scholar 19 Davie CA, Wening G, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995; 37: 204–210. 10.1002/ana.410370211 CASPubMedWeb of Science®Google Scholar 20 Lemmens GM, Ellis C, Williams SCR, et al. Proton magnetic resonance spectroscopy in striatonigral degeneration and Parkinson's disease with motor oscillations [Abstract]. Neurology 1996; 46(suppl): 6–98. Google Scholar 21 Ellis CM, Lemmens G, Williams SCR, et al. Changes in putamen N-acetylaspartate and choline ratios in untreatedand levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 1997; 49: 438–444. 10.1212/WNL.49.2.438 CASPubMedWeb of Science®Google Scholar 22 Bowen BC, Block RE, Sanchez-Ramos J, et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson's disease. Am J Neuroradiol 1995; 16: 61–68. CASPubMedWeb of Science®Google Scholar 23 Prichard J, Rothman D, Novotny E, et al. Lactate rise detected by 1H NMR in human visual cortex during physiological stimulation. Proc Natl Acad Sci USA 1991; 81: 5829–5831. 10.1073/pnas.88.13.5829 Web of Science®Google Scholar 24 Kuwabara T, Watanabe H, Tsuji S, Yuasa T. Lactate rise in the basal ganglia accompanying finger movements: a localised 1H-MRS study. Brain Res 1995; 670: 326–328. 10.1016/0006-8993(94)01353-J CASPubMedWeb of Science®Google Scholar 25 Zijlmans JCM, De Koster A, Van't Hof MA, et al. Proton magnetic resonance spectroscopy in suspected vascular ischemic parkinsonism. Acta Neurol Scand 1994; 90: 405–411. 10.1111/j.1600-0404.1994.tb02749.x CASPubMedWeb of Science®Google Scholar 26 Davie CA, Pirtosek Z, Barker GJ, Kingsley DPE, Miller DH, Lees AJ. Magnetic resonance spectroscopic study of parkinsonism related to boxing. J Neurol Neurosurg Psychiatry 1995; 58: 688–691. 10.1136/jnnp.58.6.688 CASPubMedWeb of Science®Google Scholar 27 Arnold DL, Matthews PM, Radda GK. Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR. Magn Reson Med 1984; 1: 307–315. 10.1002/mrm.1910010303 CASPubMedWeb of Science®Google Scholar 28 Matthews PM, Berkovic SF, Shoubridge EA, et al. In vivo spectroscopy of brain and muscle in a type of mitochondrial encephalomyopathy (MERRF). Ann Neurol 1991b; 29: 435–438. 10.1002/ana.410290416 PubMedWeb of Science®Google Scholar 29 Matthews PM, Andermann F, Silver K, Karpati G, Arnold DL. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 1993; 43: 2484–2490. 10.1212/WNL.43.12.2484 PubMedWeb of Science®Google Scholar 30 Penn AMW, Roberts T, Hodder J, et al. Generalised mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 1995; 45: 2097–2099. 10.1212/WNL.45.11.2097 CASPubMedWeb of Science®Google Scholar 31 Federico F, Simone Il, Lucivero V, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997; 62: 239–242. 10.1136/jnnp.62.3.239 CASPubMedWeb of Science®Google Scholar 32 Davie CA, Barker GJ, Machado C, Miller DH, Lees AJ. 1H magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord (in press). Google Scholar 33 Tedeschi G, Litvan I, Bonavita S, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997; 120: 1541–1552. 10.1093/brain/120.9.1541 PubMedWeb of Science®Google Scholar Citing Literature Volume13, Issue1January 1998Pages 2-4 ReferencesRelatedInformation
Publication Year: 1998
Publication Date: 1998-01-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 139
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot